A child with severe hearing loss associated with maternal cisplatin treatment during pregnancy.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 25004323.
- Also identified by DOI 10.1097/AOG.0000000000000389.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Cisplatin is considered safe to use during the second and third trimesters of pregnancy in patients with cancer. A 34-year-old pregnant woman was diagnosed with cervical cancer. She received five weekly dosages of cisplatin and paclitaxel, starting at 26 5/7 weeks of gestation. An elective cesarean delivery was performed at 34 4/7 weeks of gestation. After birth, the neonate was diagnosed with severe bilateral perceptive hearing loss. Cisplatin during the second and third trimesters of pregnancy may lead to fetal ototoxicity.
Medical subject headings
- Antineoplastic Agents
- Carcinoma, Squamous Cell
- Cisplatin
- Hearing Loss, Bilateral
- Pregnancy Complications, Neoplastic
- Uterine Cervical Neoplasms